Bioequivalence Study of Fixed Dose Combinations of Saxagliptin/Metformin Extended Release (XR) Relative to Co-administration of the Individual Components in Healthy Subjects in the Fasted and Fed States.
Phase of Trial: Phase I
Latest Information Update: 18 Jul 2014
At a glance
- Drugs Saxagliptin/metformin (Primary) ; Metformin; Saxagliptin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 08 Dec 2011 Actual end date (November 2011) added as reported by ClinicalTrials.gov.
- 08 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Oct 2011 Planned end date changed from 1 Aug 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.